Dual Antiplatelet Therapy

Medtronic announced that the FDA approved an expanded indication for a drug-eluting stent to include patients with high bleeding risk who take dual antiplatelet therapy for 1 month after PCI.

The landmark TAILOR-PCI trial showed encouraging evidence for genotype-guided antiplatelet therapy.

Among patients who underwent PCI for ACS and then had dual antiplatelet therapy with aspirin and prasugrel, halving the prasugrel dose after 1 month conferred reduced risk for net adverse clinical events, researchers reported.

At 1 year, aspirin plus ticagrelor after CABG was associated with similar saphenous vein graft occlusion, graft failure and bleeding compared with aspirin alone, according to results from the POPular CABG trial.

Results from the POPULAR TAVI trial demonstrated that omitting clopidogrel after transcatheter aortic valve replacement may reduce bleeding, and aspirin alone may be sufficient to prevent thromboembolic events, researchers reported.

Boston Scientific announced that its bioabsorbable polymer stent platform has received a new indication from the FDA to treat patients at high bleeding risk.

YouTube was found to be an effective tool for educating patients who had PCI for MI on their condition and the significance of adherence to their prescribed dual antiplatelet therapy, researchers reported.